Trastuzumab Provides a Comparable Prognosis in Patients With HER2-Positive Breast Cancer to Those With HER2-Negative Breast Cancer: Post Hoc Analyses of a Randomized Controlled Trial of Post-Mastectomy Hypofractionated Radiotherapy
Background and PurposeWe investigated the locoregional effect of trastuzumab, and determined whether patients with human epidermal growth factor receptor (HER)2-positive breast cancer (BC) treated with trastuzumab could achieve comparable efficacy to that of patients with HER2-negative BC.Materials...
Main Authors: | Guang-Yi Sun, Hao Jing, Shu-Lian Wang, Yong-Wen Song, Jing Jin, Hui Fang, Yue-Ping Liu, Hua Ren, Yu Tang, Xu-Ran Zhao, Yu-Chun Song, Si-Ye Chen, Zhuan-Bo Yang, Bo Chen, Yuan Tang, Ning Li, Ning-Ning Lu, Shu-Nan Qi, Yong Yang, Ye-Xiong Li |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-01-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2020.605750/full |
Similar Items
-
Cardiac Safety of Trastuzumab on 185 Patients with HER2 Positive Breast Cancer
by: MENG Wenjing, et al.
Published: (2018-02-01) -
Modelling hypersensitivity to trastuzumab defines biomarkers of response in HER2 positive breast cancer
by: Laura Díaz-Gil, et al.
Published: (2021-10-01) -
Vasculogenic mimicry is associated with trastuzumab resistance of HER2-positive breast cancer
by: Ami Hori, et al.
Published: (2019-08-01) -
Do early HER2-overexpression breast cancer patients benefit from undergoing neoadjuvant trastuzumab and mastectomy? A meta-analysis
by: He L, et al.
Published: (2019-08-01) -
The role of autophagy in the cytotoxicity induced by trastuzumab emtansine (T-DM1) in HER2-positive breast cancer cells
by: Peipei Liu, et al.
Published: (2020-06-01)